Concepedia

Samuel Ejadi

SE

24

Publications

3.2K

Citations

18

H-Index

1988

Active since

Affiliations

Seoul National University Hospital(Current)

The University of Texas MD Anderson Cancer Center

Merck & Co., Inc., Rahway, NJ, USA (United States)

Princess Margaret Cancer Centre

Mayo Clinic in Arizona

Samuel Ejadi is an author at Seoul National University Hospital specializing in oncology, medicine, and radiation oncology.

Top concepts

Publications per year

1988–2020

24

Publications

24

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

David S. Hong, Yoon‐Koo Kang, Mitesh J. Borad et al. · British Journal of Cancer · 2020 · 850 citations · Full text

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

Chiun Hsu, Se‐Hoon Lee, Samuel Ejadi et al. · Journal of Clinical Oncology · 2017 · 457 citations

, , +17

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

Aaron R. Hansen, Christophe Massard, Patrick A. Ott et al. · Annals of Oncology · 2018 · 364 citations

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

Bert H. O’Neil, John M. Wallmark, David Lorente et al. · PLoS ONE · 2017 · 299 citations · Full text

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

Patrick A. Ott, Sarina A. Piha‐Paul, Pamela N. Münster et al. · Annals of Oncology · 2017 · 250 citations · Full text

Rows per page

1–5 of 24